Loading...
•
Mar 31, 2023
BioCryst Q1 2023 Earnings Report
BioCryst reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
BioCryst's Q1 2023 earnings report showed strong growth in ORLADEYO net revenue, increasing 38% year-over-year to $68.4 million. The company's new patient growth also saw a significant rise, with a 46% increase in patients on therapy year-over-year. BioCryst anticipates ORLADEYO net revenue to be no less than $320 million for the full year 2023.
ORLADEYO net revenue grew 38 percent year-over-year to $68.4 million.
New patient growth in Q1 was strong, with a 46 percent increase in patients on therapy year-over-year.
Over 1,000 U.S. patients are on ORLADEYO therapy.
ORLADEYO net revenue in 2023 is expected to be no less than $320 million.
Forward Guidance
The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. Operating expenses for full year 2023, not including non-cash stock compensation, are expected to be flat to 2022 at approximately $375 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...